Skip to main content
SpringerLink
Log in

Chemotherapy of advanced non-small cell lung cancer

A review

  • Review Article
  • Published:
Investigational New Drugs Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Bibliography

  1. Greco FA, Oldham RK: Current concepts in cancer: Small cell lung cancer. New Engl J Med 301:355–358, 1979

    Google Scholar 

  2. Aisner J, Hansen HH: Commentary: Current status of chemotherapy for non-small cell lung cancer. Cancer Treat Rep 65:979–986, 1981

    Google Scholar 

  3. Hoffman PC, Bitran JD, Golomb HM: Chemotherapy of metastatic non-small cell bronchogenic carcinoma. Semin Oncol 10:111–122, 1983

    Google Scholar 

  4. Green RA, Humphrey E, Close H, Patno ME: Alkylating agents in bronchogenic carcinoma. Am J Med 46:516–525, 1969

    Google Scholar 

  5. Selawry OS: Response of bronchogenic carcinoma to adriamycin. Cancer Chemother Rep 76:349–351, 1975

    Google Scholar 

  6. Gralla RJ, Raphael BG, Golbey RB, Young CW: Phase II evaluation of vindesine in patients with non-small cell carcinoma of the lung. Cancer Treat Rep 63: 1343–1346, 1979

    Google Scholar 

  7. Mattson K, Holsti LR, Salmo M, Saastamoinen M, Ahlstedt S, Holsti P: Vindesine in the treatment of small cell and non-small cell bronchogenic carcinoma: Preliminary results. Cancer Treat Rev 7 (Supplement):65–70, 1980

    Google Scholar 

  8. Valdivieso M: Phase I and II studies of vindesine. Cancer Treat Rev 7 (Supplement):31–37, 1980

    Google Scholar 

  9. Furnas BE, Williams SD, Einhorn LH, Cobleigh MA: Vindesine: An effective agent in the treatment of non-small cell lung cancer. Cancer Treat Rep 66:1709–1711, 1982

    Google Scholar 

  10. Luedke SL, Leudke DW, Petruska P, Broun GO, Reed G, Leavitt J: Vindesine monochemotherapy for non-small cell lung cancer: A report of 45 cases. Cancer Treat Rep 66: 1409–1411, 1982

    Google Scholar 

  11. Østerlind K, Hørbov S, Dombernowsky P, Rorth M, Hansen HH: Vindesine in the treatment of squamous cell carcinoma, adenocarcinoma, and large cell carcinoma of the lung. Cancer Treat Rep 66:305–309, 1982

    Google Scholar 

  12. Dirks HP, Drings P, Manke HG, Vollhaber HH: Continuous vindesine infusion therapy in cases of advanced non-small cell bronchogenic carcinoma. In: Brade W, Nagel GA, and Seeber S (eds): Proceedings of the International Vinca Alkaloid Symposium-Vindesine. S. Karger, Basel, 1981, pp 344–349

    Google Scholar 

  13. Boston B, Getaz EP, Buchanan M: Randomized comparison of vindesine vs DVA and CIS-Platin in non-small cell lung cancer (Abstract). Proc Am Assoc Cancer Res and Am Soc Clin Oncol 22:504, 1981

    Google Scholar 

  14. Hong WK, Pennacchio J, Pugatch R, Krikorian J, Bromer R, Lopez J, Faling LJ, Snider G: Vindesine versus vindesine with CIS-platinum in metastatic non-small cell lung cancer. In: Brade W, Nagel GA, and Seeber S (eds): Proceedings of the International Vinca Alkaloid Symposium-Vindesine. S. Karger, Basel, 1981, pp 398–404

    Google Scholar 

  15. Elliott JA, Ahmedzai S, Stevenson RD, Dorward AJ, Calman KC: Randomized comparison of vindesine versus vindesine plus CIS-platinum in inoperable non-small cell lung cancer. Abstr. III World Conf on Lung Cancer, Tokyo, Japan, May 17–20, 1982 p 192

  16. Souhami RL, Tobias JS, Spiro SG, Jewkes J, Harper PG, Geddes DM: Response to vindesine or vincristine in inoperable non-small cell carcinoma of the bronchus. Abstr. III World Conf on Lung Cancer, Tokyo, Japan, May 17–20, 1982, p 179

  17. Saiers JH, Slavik M, McKinney DR: Phase II study of vindesine in lung cancer (Abstract). Proc Am Soc Clin Oncol 2: 192, 1983

    Google Scholar 

  18. Frei E, Franzino A, Shnider BI, Costa G, Colsky J, Brindley CO, Hosley H, Holland JF, Gold GL, Jonsson U: Clinical studies of vinblastine. Cancer Chemother Rep 12:125–129, 1961

    Google Scholar 

  19. Hill JM, Loeb E: Treatment of leukemia, lymphoma, and other malignant neoplasms with vinblastine. Cancer Chemother Rep 15:41–61, 1961

    Google Scholar 

  20. Wright TL, Hurley J, Korst DR, Monto RW, Rohn RJ, Will JJ, Louis J: Vinblastine in neoplastic disease. Cancer Res 23:169–179, 1963

    Google Scholar 

  21. Armstrong JG, Dyke RW, Fouts PJ, Gahimer JE: Hodgkin's disease, carcinoma of the breast, and other tumors treated with vinblastine sulfate. Cancer Chemother Rep 18:49–71, 1962

    Google Scholar 

  22. A Cooperative Study. Neoplastic disease-treatment with vinblastine. Arch Int Med 116:846–852, 1965

  23. Zeffren J, Yagoda A, Kelsen D, Winn R: Phase I trial of a 5-day infusion of vinblastine (Abstract). Proc Am Assoc Cancer Res and Am Soc Clin Oncol 21:178, 1980

    Google Scholar 

  24. Schulman P, Budman DR, Vinciguerra V, Weiselberg L, Abrams S, Degnan T: Phase II study of divided dose vinblastine sulfate in non-small cell lung carcinoma (Abstract). Proc Am Assoc Cancer Res and Am Soc Clin Oncol 22:504, 1981

    Google Scholar 

  25. Rossof AH, Bearden JD, Coltman CA: Phase II evaluation of CIS-diamminedichloroplatinum (II) in lung cancer. Cancer Treat Rep 60:1679–1680, 1976

    Google Scholar 

  26. Britell JC, Eagan RT, Ingle JN, Creagan ET, Rubin J, Frytak S: CIS-dichlorodiammineplatinum (II) alone followed by adriamycin plus cyclophosphamide at progression versus CIS-dichlorodiammine-platinum (II), adriamycin, and cyclophosphamide in combination for adenocarcinoma of the lung. Cancer Treat Rep 62:1207–1210, 1978

    Google Scholar 

  27. Casper ES, Gralla RJ, Kelsen DP, Cvitkovic E, Golbey RB: Phase II study of high-dose CIS-dichlorodiammineplatinum (II) in the treatment of non-small cell lung cancer. Cancer Treat Rep 63:2107–2109, 1979

    Google Scholar 

  28. DeJager R, Longeval E, Klastersky J: High-dose CISplatin with fluid and mannitol-induced diuresis in advanced lung cancer: a phase II clinical trial of the EORTC lung cancer working party (Belgium). Cancer Treat Rep 64:1341–1346, 1980

    Google Scholar 

  29. Panettiere FJ: Effects of the two dose SWOG CIS-platinum (CACP) program in non-oat cell lung cancer (Abstract). Proc Am Assoc Cancer Res and Am Soc Clin Oncol 21:450, 1980

    Google Scholar 

  30. Vogl SE, Berenzweig M, Camacho F, Greenwald E, Kaplan BH: Efficacy study of intensive CIS-platin therapy in advanced non-small cell bronchogenic carcinoma. Cancer 50: 24–26, 1982

    Google Scholar 

  31. Samson MK, Comis RL, Baker LH, Ginsberg S, Fraile RJ, Crooke ST: Mitomycin C in advanced adenocarcinoma and large cell carcinoma of the lung. Cancer Treat Rep 62:163–165, 1978

    Google Scholar 

  32. Koons LS, Harris DT, Engstrom PF: Mitomycin C chemotherapy in advanced squamous cell carcinoma of the lung (Abstract). Proc Am Assoc Cancer Res and Am Soc Clin Oncol 19:326, 1978

    Google Scholar 

  33. Edmonson JH, Lagakos SW, Selawry OS, Perlia CP, Bennett JM, Muggia FM, Wampler G, Brodovsky HS, Horton J, Colsky J, Mansour EG, Creech R, Stolbach L, Greenspan EM, Levitt M, Israel L, Ezdinli EZ, Carbone PP: Cyclophosphamide and CCNU in the treatment of inoperable small cell carcinoma and adenocarcinoma of the lung. Cancer Treat Rep 60:925–932, 1976

    Google Scholar 

  34. Einhorn LH, Williams SD, Stevens EE, Bond WH, Chemoweth L: Random prospective study of cyclophosphamide, doxorubicin, and methotrexate (CAM) combination chemotherapy versus single-agent sequential chemotherapy in non-small cell lung cancer. Cancer Treat Rep 66:2005–2011, 1982

    Google Scholar 

  35. Corbett TH, Griswold DP, Mayo JG, Laster WR, Schabel FM: Cyclophosphamide-adriamycin combination chemotherapy of transplantable murine tumors. Cancer Res 35:1568–1573, 1975

    Google Scholar 

  36. Wolf J, Zelen M: Comparative trial of two drug combination in pulmonary cancer (Abstract). Proc Am Assoc Cancer Res and Am Soc Clin Oncol 16:272, 1975

    Google Scholar 

  37. Lloyd RE, Jones SE, Salmon SE, Durie BGM, McMahon LJ: Combination chemotherapy with adriamycin (NSC-123127) and cyclophosphamide (NSC-26271) for solid tumors: a phase II trial. Cancer Treat Rep 60:77–83, 1976

    Google Scholar 

  38. Tancini G, Marchini S: Adriamycin plus cyclophosphamide in advanced bronchial carcinoma. Tumori 62:373–376, 1976

    Google Scholar 

  39. Higby DJ, Wilbur D, Wallace HJ, Henderson ES, Weiss R: Adriamycin-cyclophosphamide and adriamycin-CIS-dichlorodiammineplatinum (II) combination chemotherapy in patients with advanced cancer. Cancer Treat Rep 61:869–873, 1977

    Google Scholar 

  40. Herman TS, Jones SE, McMahon LJ, Lloyd RE, Heusinkveld RS, Miller RC, Salmon SE: Combination chemotherapy with adriamycin and cyclophosphamide (with or without radiation therapy) for carcinoma of the lung. Cancer Treat Rep 61:875–879, 1977

    Google Scholar 

  41. Luedke D, Luedke S, Petruska P, Gallagher N, Broun GO: A randomized prospective study of vindesine versus doxorubicin and cyclophosphamide in the treatment of advanced squamous cell carcinoma of the lung (Abstract). Proc Am Assoc Cancer Res and Am Soc Clin Oncol 22:499, 1981

    Google Scholar 

  42. Robert FR, Birch R, Krauss S, Oldham R, Omura G: Randomized comparison of cyclophosphamide, adriamycin, methotrexate and folinic acid versus cyclophosphamide, adriamycin and CIS-platinum versus cyclophosphamide and adriamycin in advanced non-small cell lung cancer (Abstract). Proc Am Assoc Cancer Res and Am Soc Clin Oncol 22:503, 1981

    Google Scholar 

  43. Bitran JD, Desser RK, DeMeester TR, Colman M, Evans R, Billings A, Griem M, Rubenstein L, Shapiro C, Golomb HM: Cyclophosphamide, adriamycin, methotrexate, and procarbazine (CAMP)-effective four-drug combination chemotherapy for metastatic non-oat cell bronchogenic carcinoma. Cancer Treat Rep 60:1225–1230, 1976

    Google Scholar 

  44. Bitran JD, Desser RK, DeMeester T, Golomb HM: Metastatic non-oat-cell bronchogenic carcinoma. Therapy with cyclophosphamide, doxorubicin, methotrexate, and procarbazine (CAMP). J Am Med Assoc 240:2743–2746, 1978

    Google Scholar 

  45. Shepard K, Bitran J, Golomb H, Newman S, DeMeester T, Skosey C: CAMP chemotherapy for metastatic non-oat cell bronchogenic carcinoma: a seven year experience (Abstract). Clin Res 30:748A, 1982

    Google Scholar 

  46. Vogelzang NJ, Bonomi PD, Rossof AH, Wolter J: Cyclophosphamide, adriamycin, methotrexate, and procarbazine (CAMP) treatment of non-oat cell bronchogenic carcinoma. Cancer Treat Rep 62:1595–1597, 1978

    Google Scholar 

  47. Cartwright TH, Moore MR, York RM, Schreiber F: Randomized comparison of a combination of cyclophosphamide, adriamycin, methotrexate, and procarbazine (CAMP) with a combination of mitomycin C, CIS-platinum, and hexamethylmelamine in metastatic non-oat cell carcinoma of the lung (Abstract). Proc Amer Assoc Cancer Res and Am Soc Clin Oncol 22:506, 1981

    Google Scholar 

  48. Lad TE, Nelson RB, Diekamp U, Kukla LJ, Sarma PR, Larson CS, Currie ET, Chawla MS, Tichler T, Zawila P, McGuire WP: Immediate versus postponed combination chemotherapy (CAMP) for unresectable non-small cell lung cancer: a randomized trial. Cancer Treat Rep 65:973–978, 1981

    Google Scholar 

  49. Ruckdeschel JC, Mason B, Ettinger D, Creech R, Mehta C, Stanley K: Chemotherapy of metastatic non-oat cell bronchogenic carcinoma: The Eastern Cooperative Oncology Group Experience. Abstr. III World Conf on Lung Cancer, Tokyo, Japan, May 17–20, 1982, p 185

  50. Luporini G, Clerici M, Labianca R, Beretta G: Reevaluation of CAMP polychemotherapy in non-small cell lung carcinoma. Abstr. III World Conf on Lung Cancer, Tokyo, Japan, May 17–20, 1982 p 180

  51. Eagan RT, Ingle JN, Frytak S, Rubin J, Kvols LK, Carr DT, Coles DT, O'Fallon JR: Platinum-based polychemotherapy versus dianhydrogalactitol in advanced non-small cell lung cancer. Cancer Treat Rep 61:1339–1345, 1977

    Google Scholar 

  52. Eagan RT, Frytak S, Creagan ET, Ingle JN, Kvols LK, Coles DT: Phase II study of cyclophosphamide, adriamycin, and CIS-dichlorodiammineplatinum (II) by infusion in patients with adenocarcinoma and large cell carcinoma of the lung. Cancer Treat Rep 63:1589–1591, 1979

    Google Scholar 

  53. Gralla RJ, Cvitkovic E, Golbey RB: CIS-dichlorodiammine-platinum (II) in non-small cell carcinoma of the lung. Cancer Treat Rep 63:1585–1588, 1979

    Google Scholar 

  54. Knost JA, Greco FA, Hande KR, Richardson RL, Fer MF, Oldham RK: Cyclophosphamide, doxorubicin, and CISplatin in the treatment of advanced non-small cell lung cancer. Cancer Treat Rep 65:941–945, 1981

    Google Scholar 

  55. Evans WK, Feld R, DeBoer G, Osoba D, Curtis JE, Baker MA, Myers RE, Quirt IC, Pritchard KI, Brown TC, Kutas GJ, Blackstein ME, Ottema B, Millband L: Cyclophosphamide, doxorubicin, and CISplatin in the treatment of non-small cell bronchogenic carcinoma. Cancer Treat Rep 65:947–954, 1981

    Google Scholar 

  56. Davis S, Rambotti P, Park YK: Combination cyclophosphamide, doxorubicin, and CISplatin (CAP) chemotherapy for extensive non-small cell carcinomas of the lung. Cancer Treat Rep 65:955–958, 1981

    Google Scholar 

  57. Abderhalden RT, Hatfield AK, Harder L: The treatment of non-small cell bronchogenic carcinoma in a community hospital (Abstract). Proc Am Assoc Cancer Res and Am Soc Clin Oncol 22:500, 1981

    Google Scholar 

  58. Krook J, Pfeifle D, Eagan R, Fleming T: CAP versus MACC in advanced adenocarcinoma and large cell carcinoma of the lung (Abstract). Proc Am Assoc Cancer Res and Am Soc Clin Oncol 22:506, 1981

    Google Scholar 

  59. Fleischer I, Wainstein R, Gibson A, Giacomi N: An open clinical trial with cyclophosphamide, adriamycin, and CIS-platinum for inoperable non oat-cell cancer. Abstr. III World Conf on Lung Cancer, Tokyo, Japan, May 17–20, 1982, p 193

  60. Miller TP, Chen TT: Alternating combination chemotherapy prolongs survival for metastatic non-small cell lung cancer (Abstract). Proc Am Soc Clin Oncol 2:188, 1983

    Google Scholar 

  61. Chahinian AP, Arnold DJ, Cohen JM, Purpora DP, Jaffrey IS, Teirstein AS, Kirschner PA, Holland JF: Chemotherapy for bronchogenic carcinoma. J Am Med Assoc 237:2392–2396, 1977

    Google Scholar 

  62. Chahinian AP, Mandel EM, Holland JF, Jaffrey IS, Teirstein AS: MACC (methotrexate, adriamycin, cyclophosphamide and CCNU) in advanced lung cancer. Cancer 43:1590–1597, 1979

    Google Scholar 

  63. Vogl SE, Mehta CR, Cohen MH: MACC chemotherapy for adenocarcinoma and epidermoid carcinoma of the lung. Low response rate in a cooperative group study. Cancer 44:864–868, 1979

    Google Scholar 

  64. Corkery J, Wilkinson J, Zipoli T, Greene R, Lokich J: Effective chemotherapy in non-oat cell cancer of the lung (Abstract). Proc Amer Assoc Cancer Res and Am Soc Clin Oncol 21:449, 1980

    Google Scholar 

  65. Milstein D, Robinson E. Four drug combination chemotherapy in advanced lung cancer (methotrexate, adriamycin, cyclophosphamide and CCNU). Abstr. III World Conf on Lung Cancer, Tokyo, Japan, May 17–20, 1982 p 133

  66. Cormier Y, Bergeron D, LaForge J, Lavandier M, Fournier M, Chenard J, Desmeulles M: Benefits of polychemotherapy in advanced non-small cell bronchogenic carcinoma. Cancer 50:845–849, 1982

    Google Scholar 

  67. Hoffman P, Newman S, Golomb H, DeMeester T, Blough R, Sovik C: Metastatic non-small cell bronchogenic carcinoma: a randomized trial of sequential versus combination chemotherapy. Abstr. III World Conf on Lung Cancer, Tokyo, Japan, May 17–20, 1982, p 178

  68. Hoffman PC, Newman SB, Golomb HM, DeMeester TR, Sovik CA, Blough RR: Treatment of stage III metastatic non-oat cell bronchogenic carcinoma: a randomized study (Abstract). Proc Amer Assoc Cancer Res and Am Soc Clin Oncol 22:500, 1981

    Google Scholar 

  69. Gralla RJ, Casper ES, Kelsen DP, Braun DW, Dukeman ME, Martini N, Young CW, Golbey RB: CISplatin and vindesine combination chemotherapy for advanced carcinoma of the lung: a randomized trial investigating two dosage schedules. Ann Int Med 95:414–420, 1981

    Google Scholar 

  70. Bölcskei P, Kleinfelder H, Krasa Z, Mattausch H, Beckh S: Experience with the combination of CIS-platinum and vindesine in the treatment of squamous cell carcinomas, adenocarcinomas and large cell bronchogenic carcinomas. In: Brade W, Nagel GA, and Seeber S (eds.): Proceedings of the International Vinca Alkaloid Symposium-Vindesine. S. Karger, Basel, 1981, pp 392–397

    Google Scholar 

  71. Gröhn P, Niitamo S, Mattson K, Holsti LR, Heinonen E, Holsti P, Niiranen A, Salmo M: Combination chemotherapy in advanced non-small cell lung cancer. Abstr. III World Conf on Lung Cancer, Tokyo, Japan, May 17–20, 1982, p 190

  72. Pajon ER, DiBella N, Meyer T, Garfield D: Vindesine and CIS-platinum in the treatment of unresectable carcinoma of the lung. Proc Am Soc Clin Oncol 1:146, 1982

    Google Scholar 

  73. Fuks JZ, Patel H, Poplin B, Van Echo DA, Aisner J: Combination chemotherapy with CISplatin and vindesine for non-small cell lung cancer (Abstract). Proc Am Soc Clin Oncol 2:196, 1983

    Google Scholar 

  74. Noguera C, Gretta-Acquatella M, Garcia JR, Dominquez RW, Morillo F, Arreaza N, Abenante CA: Ambulatory chemotherapy with vindesine and platinum for stage III non-small cell lung carcinoma (Abstract). Proc Am Soc Clin Oncol 2:204, 1983

    Google Scholar 

  75. Niederle N, Schütte J, Roer N, Seeber S, Schmidt CG: Inoperable large cell carcinoma of the lung — treatment with vindesine and CISplatin (Abstract). Proc Am Assoc Cancer Res 24:153, 1983

    Google Scholar 

  76. Bitran JD, Desser RK, Shapiro CM: Velban and CIS-platin in the treatment of refractory stage III M1 non-small cell bronchogenic carcinoma (Abstract). Proc Am Assoc Cancer Res and Am Soc Clin Oncol 22:501, 1981

    Google Scholar 

  77. Stoopler MB, Jaretzki A, Rakowski TJ, Garrett J, Ellison RR: Vinblastine and CIS-Dichlorodiammineplatinum combination chemotherapy in non-small cell lung cancer (Abstract). Proc Am Soc Clin Oncol 1:141, 1982

    Google Scholar 

  78. Woodcock TM, Blumenreich MS, Richman SP, Kubota TT, Gentile PS, Allegra JC: Combination chemotherapy with CIS-Diamminedichloroplatinum and vinblastine in advanced non-small cell lung cancer. J Clin Oncol 1:247–250, 1983

    Google Scholar 

  79. Halibey B, Lippman A, Custodio M, Steinbaum F, Cohen F: Clinical Trial of CIS-Diamminedichloroplatinum and vinblastine in non-small cell lung carcinoma (Abstract). Proc Am Soc Clin Oncol 2:202, 1983

    Google Scholar 

  80. Hetzel P: Treatment of non-small cell lung cancer in a community seting with vinblastine and CIS-dichlorodiamineplatinum (Abstract). Proc Am Soc Clin Oncol 2:204, 1983

    Google Scholar 

  81. Huberman M, Greene R, Lokich J, Paul S, Phillips D, Sonneborn H, Zipoli T: Five day infusion vinblastine and bolus CIS-platinum in the treatment of advanced non-small cell lung cancer (Abstract). Proc Am Soc Clin Oncol 2:205, 1983

    Google Scholar 

  82. Kalman LA, Kris MG, Gralla RJ, Kelsen DP, Casper ES, Heelan RT, Burke MT, Golbey RB: Vinca alkaloid and CIS-platin combination therapy in non-small cell lung cancer: results of a randomized trial with comparison of methods of response assessment in 109 patients (Abstract). Proc Am Soc Clin Oncol 2:201, 1983

    Google Scholar 

  83. Yap HY, Blumenschein GR, Keating MJ, Hortobagyi GN, Tashima CK, Loo TL: Vinblastine given as a continuous 5-day infusion in the treatment of refractory advanced breast cancer. Cancer Treat Rep 64:279–283, 1980

    Google Scholar 

  84. Yap HY, Blumenschein GR, Bodey GP, Hortobagyi GN, Buzdar AU, DiStefano A: Continuous 5-day infusion vindesine-improvement in therapeutic index in the treatment of refractory breast cancer (Abstract). Proc Am Assoc Cancer Res and Am Soc Clin Oncol 21:408, 1980

    Google Scholar 

  85. Kelsen D, Gralla R, Stoopler M, Casper E, Cheng E, Kosloff C, Golbey R: CISplatin, doxorubicin, cyclophosphamide, and vindesine combination chemotherapy for non-small cell lung cancer. Cancer Treat Rep 66:247–251, 1982

    Google Scholar 

  86. Mason BA, Catalano RB: Mitomycin, vinblastine and CISplatin combination chemotherapy in non-small cell lung cancer (Abstract). Proc Am Assoc Cancer Res and Am Soc Clin Oncol 21:447, 1980

    Google Scholar 

  87. Schulman P, Budman DR, Vinciguerra V, Weiselberg L, Degnan TJ: A phase II study of mitomycin C, vinblastine and CIS-platin in non-small cell bronchogenic carcinoma (Abstract). Proc Am Soc Clin Oncol 1:150, 1982

    Google Scholar 

  88. Chang Y-CA, Kuebler PJ, Tormey DC, Pandya KJ, Borden EC, Davis TE, Love RR, Carbone PP: A phase II evaluation of combined mitomycin C, vincristine, CIS-platinum in advanced non-small cell lung cancer (Abstract). Proc Am Soc Clin Oncol 1:139, 1982

    Google Scholar 

  89. Goldie JH, Coldman AJ, Gudauskas GA: Rationale for the use of alternating non-cross-resistant chemotherapy. Cancer Treat Rep 66:439–449, 1982

    Google Scholar 

  90. Santoro A, Bonadonna G, Bonfante V, Valagussa P: Alternating drug combinations in the treatment of advanced Hodgkin's disease. N Engl J Med 306:770–775, 1982

    Google Scholar 

  91. Stanley KE: Prognostic factors for survival in patients with inoperable lung cancer. JNCI 65:25–32, 1980

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Section of Hematology/Oncology, Department of Internal Medicine and the Cancer Center, University of Arizona, USA

    Bonnie J. Takasugi & Thomas P. Miller M.D.

  2. the Veterans Administration Hospital, Tucson, Arizona, USA

    Bonnie J. Takasugi & Thomas P. Miller M.D.

Authors
  1. Bonnie J. Takasugi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Thomas P. Miller M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Takasugi, B.J., Miller, T.P. Chemotherapy of advanced non-small cell lung cancer. Invest New Drugs 2, 339–347 (1984). https://doi.org/10.1007/BF00175389

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00175389

Key words

Search

Navigation